Federal Old-Age, Survivors and Disability Insurance (1950- ), 85104 [2023-26983]
Download as PDF
<![CDATA[
85104
Federal Register / Vol. 88, No. 234 / Thursday, December 7, 2023 / Rules and Regulations
Country
License
requirement
Entity
R2, Sharjah Airport Free Zone Street,
Office 806, Sharjah, United Arab
Emirates; and PO Box 120683, SaifZone, Sharjah, United Arab Emirates;
and . SM-Office E1–1414D, Ajman
Free Zone, Ajman, United Arab Emirates.
*
*
*
*
*
*
*
License review policy
*
*
DEPARTMENT OF JUSTICE
Matthew S. Borman,
Deputy Assistant Secretary for Export
Administration.
Drug Enforcement Administration
21 CFR Part 1308
[FR Doc. 2023–26935 Filed 12–5–23; 11:15 am]
[Docket No. DEA–1036]
BILLING CODE 3510–33–P
Schedules of Controlled Substances:
Placement of Nine Specific FentanylRelated Substances in Schedule I
SOCIAL SECURITY ADMINISTRATION
20 CFR Part 404
Drug Enforcement
Administration, Department of Justice.
ACTION: Final rule.
Federal Old-Age, Survivors and
Disability Insurance (1950– )
SUMMARY:
CFR Correction
This rule is being published by the
Office of the Federal Register to correct
an editorial or technical error that
appeared in the most recent annual
revision of the Code of Federal
Regulations.
In Title 20 of the Code of Federal
Regulations, Parts 400 to 499, revised as
of April 1, 2023, in Appendix I to
Subpart P of Part 404, in Part B, section
101.00, revise the first sentence of
paragraph C.7.c. to read as follows:
■
Appendix 1 to Subpart P of Part 404—
Listing of Impairments
*
*
*
*
*
*
*
*
Part B
*
*
101.00
ddrumheller on DSK120RN23PROD with RULES1
*
*
Musculoskeletal Disorders.
*
*
*
C. * * *
7. * * *
c. For 101.15, 101.16, 101.17, 101.18,
101.20C, 101.20D, 101.22, and 101.23, all of
the required criteria must be present
simultaneously, or within a close proximity
of time, to satisfy the level of severity needed
to meet the listing. * * *
[FR Doc. 2023–26983 Filed 12–6–23; 8:45 am]
BILLING CODE 0099–10–P
VerDate Sep<11>2014
17:30 Dec 06, 2023
Jkt 262001
AGENCY:
With the issuance of this final
rule, the Drug Enforcement
Administration places nine fentanylrelated substances, as identified in this
final rule, including their isomers,
esters, ethers, salts, and salts of isomers,
esters, and ethers whenever the
existence of such isomers, esters, ethers,
and salts is possible, in schedule I of the
Controlled Substances Act. These nine
fentanyl-related substances are currently
listed in schedule I pursuant to a
temporary scheduling order. This action
makes permanent the imposition of the
regulatory controls and administrative,
civil, and criminal sanctions applicable
to schedule I controlled substances on
persons who handle (manufacture,
distribute, import, export, engage in
research, conduct instructional
activities or chemical analysis with, or
possess), or propose to handle these
nine specific fentanyl-related controlled
substances.
DATES: Effective date: December 7, 2023.
FOR FURTHER INFORMATION CONTACT: Dr.
Terrence L. Boos, Drug and Chemical
Evaluation Section, Diversion Control
Division, Drug Enforcement
Administration; Telephone: (571) 362–
3249.
SUPPLEMENTARY INFORMATION: In this
rule, the Drug Enforcement
Administration (DEA) is permanently
scheduling the following nine
controlled substances including their
isomers, esters, ethers, salts, and salts of
isomers, esters, and ethers whenever the
existence of such isomers, esters, ethers,
and salts is possible, in schedule I of the
Controlled Substances Act (CSA):
PO 00000
Frm 00012
Fmt 4700
Sfmt 4700
Federal Register citation
*
*
• meta-fluorofentanyl (N-(3fluorophenyl)-N-(1-phenethylpiperidin4-yl)propionamide),
• meta-fluoroisobutyryl fentanyl (N(3-fluorophenyl)-N-(1phenethylpiperidin-4-yl)isobutyramide),
• para-methoxyfuranyl fentanyl (N(4-methoxyphenyl)-N-(1phenethylpiperidin-4-yl)furan-2carboxamide),
• 3-furanyl fentanyl (N-(1phenethylpiperidin-4-yl)-Nphenylfuran-3-carboxamide),
• 2′,5′-dimethoxyfentanyl (N-(1-(2,5dimethoxyphenethyl)piperidin-4-yl)-Nphenylpropionamide),
• isovaleryl fentanyl (3-methyl-N-(1phenethylpiperidin-4-yl)-Nphenylbutanamide),
• ortho-fluorofuranyl fentanyl (N-(2fluorophenyl)-N-(1-phenethylpiperidin4-yl)furan-2-carboxamide),
• alpha′-methyl butyryl fentanyl (2methyl-N-(1-phenethylpiperidin-4-yl)N-phenylbutanamide), and
• para-methylcyclopropyl fentanyl
(N-(4-methylphenyl)-N-(1phenethylpiperidin-4yl)cyclopropanecarboxamide).
Legal Authority
The CSA provides that proceedings
for the issuance, amendment, or repeal
of the scheduling of any drug or other
substance may be initiated by the
Attorney General (1) on his own motion;
(2) at the request of the Secretary of the
Department of Health and Human
Services (HHS); 1 or (3) on the petition
of any interested party.2 This action was
initiated on the Attorney General’s own
motion, as delegated to the
Administrator of the DEA
(Administrator), and is supported by,
inter alia, a recommendation from the
Assistant Secretary for Health of HHS
1 As discussed in a memorandum of
understanding entered into by the Food and Drug
Administration (FDA) and the National Institute on
Drug Abuse (NIDA), FDA acts as the lead agency
within HHS in carrying out the Secretary’s
scheduling responsibilities under the CSA, with the
concurrence of NIDA. 50 FR 9518, Mar. 8, 1985.
The Secretary of HHS has delegated to the Assistant
Secretary for Health of HHS the authority to make
domestic drug scheduling recommendations. 58 FR
35460, July 1, 1993.
2 21 U.S.C. 811(a).
E:\FR\FM\07DER1.SGM
07DER1
]]>Agencies
[Federal Register Volume 88, Number 234 (Thursday, December 7, 2023)]
[Rules and Regulations]
[Page 85104]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-26983]
=======================================================================
-----------------------------------------------------------------------
SOCIAL SECURITY ADMINISTRATION
20 CFR Part 404
Federal Old-Age, Survivors and Disability Insurance (1950- )
CFR Correction
This rule is being published by the Office of the Federal Register
to correct an editorial or technical error that appeared in the most
recent annual revision of the Code of Federal Regulations.
0
In Title 20 of the Code of Federal Regulations, Parts 400 to 499,
revised as of April 1, 2023, in Appendix I to Subpart P of Part 404, in
Part B, section 101.00, revise the first sentence of paragraph C.7.c.
to read as follows:
Appendix 1 to Subpart P of Part 404--Listing of Impairments
* * * * *
Part B
* * * * *
101.00 Musculoskeletal Disorders.
* * * * *
C. * * *
7. * * *
c. For 101.15, 101.16, 101.17, 101.18, 101.20C, 101.20D, 101.22,
and 101.23, all of the required criteria must be present
simultaneously, or within a close proximity of time, to satisfy the
level of severity needed to meet the listing. * * *
[FR Doc. 2023-26983 Filed 12-6-23; 8:45 am]
BILLING CODE 0099-10-P
